Summit addresses strategies to accommodate changing regulatory environment
REDWOOD CITY, Calif. – December 8, 2015 – Model N, Inc. (NYSE: MODN), the leading provider of cloud-based Revenue Management solutions to life science, technology and manufacturing companies, announces the Regulatory Summit on December 9, 2015 at the Tre Piani in Princeton, NJ to discuss new rulings and best practices for the pharmaceutical industry.
Over 60 percent of pharmaceutical executives perceive regulatory and legislative issues to be the “most significant barrier to their company’s growth,” according to a study conducted by KPMG that surveyed 107 senior pharmaceutical executives, with 45 percent of respondents working at companies with annual revenues over $10 billion.
“Model N continues to demonstrate its commitment to the regulatory changes affecting the pharmaceutical industry,” said Dan Bayer, Vice President and GM, Life Sciences at Model N. “We are a long-term partner for our customers to ensure they stay up-to-date and compliant through our Regulatory Update Program.”
The regulatory summit will include:
- Latest updates on AMP & other regulations
- Latest capabilities of Model N Medicaid and GP
- Best practices for Medicaid and GP
- Networking with colleagues and industry thought leaders
For more information and to register, please visit http://pages.modeln.com/Regulatory-Summit-Invite.html
About Model N
Model N is the leader in Revenue Management Cloud solutions for life science, technology and manufacturing companies. Driving mission critical business processes such as configure, price and quote (CPQ), contract management, rebates and regulatory compliance, Model N Cloud solutions transform the revenue lifecycle from a series of disjointed operations into a strategic end-to-end process. With deep industry expertise, Model N supports the unique business needs of the world’s leading brands in life science, technology and manufacturing across more than 100 countries.
Model N is a trusted partner to some of the world’s largest brands, including Johnson & Johnson, AstraZeneca, Boston Scientific, Novartis, Ortho Clinical Diagnostics, Atmel, Fairchild and Marvell. Model N trades on the New York Stock Exchange under the symbol MODN.
Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.
Connect with Model N